Skip to content

Evaluation of Patients With Diffuse Parenchymal Lung Diseases Regarding Frailty

Diffüz Parankimal Akciğer Hastalarında Kırılganlık Düzeyi, Egzersiz Kapasitesi ve Denge Değerlendirilmesi

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06171425
Enrollment
28
Registered
2023-12-14
Start date
2023-12-25
Completion date
2024-02-22
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Parenchymal Lung Disease, Frailty, Physical Inactivity

Brief summary

There are very few studies in the literature examining the frailty levels of diffuse parenchymal lung disease (DPLD) patients and its effect on their functional status despite the high prevalance of frailty in patients with DPLD This observational study aims to learn about the relationship between frailty and functional capacity and balance in DPLD patients compared to healthy subjects.

Detailed description

The aim of the study is to evaluate the relationship between the level of frailty and exercise capacity, respiratory functions, diffusion capacity, balance level, postural changes, activities of daily living, peripheral muscle strength and quality of life parameters in DPLD patients. The second aim is to compare diffuse parenchymal lung patients and the healthy control group in terms of these parameters.

Interventions

None listed

Sponsors

Hacettepe University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Being diagnosed with Diffuse parenchymal lung according to the American Thoracic Society/European Respiratory Society (ATS/ERS) criteria, * Being between the ages of 30-65, * Being literate, * Being willing to participate in the research, * Being clinically stable and having any accompanying comorbid conditions (such as hypertension, diabetes) under control, * Not having any orthopedic, metabolic or neurological problems that may prevent evaluation of peripheral muscle strength, balance and exercise capacity.

Exclusion criteria

* Having recently experienced syncope, * Having a history of unstable cardiovascular disease, * Having been hospitalized due to exacerbation in the last 3 months, * Having received pulmonary rehabilitation in the last 12 months, * Having a neurological disease, * Being dependent and using a walking aid while performing the person's daily life activities, * Having a pacemaker, * Having a diagnosis of lung cancer

Design outcomes

Primary

MeasureTime frameDescription
frailty level1 time which will be in one dayevaluation of frailty level with Fried Frailty Criteria which are weight loss existence, muscle strength, physical activity (will be measured with International Physical Activity Questionnaire), mobility (will be measured by 4-meter walking test), and depression level. Fried frailty phenotype consists of five criteria: loss, exhaustion, physical inactivity, low hand grip strength, and slow walking speed. Patients who have three or more of these criteria are defined as frail, those who have one or two criteria, are defined as prefrail, and none of the criteria are defined as robust.

Secondary

MeasureTime frameDescription
exercise capacity1 time which will be in one dayby 1 minute sit to stand test
balance measurementday 1by timed up and go test
posture analysisday 1corbin postural assesment scale from lateral and posterior view will be applied. The Corbin Posture Scale is a postural assessment scale that evaluates the inclination of the head in different directions, the shape of the dorsal region, the presence of scapulaand shoulder protraction, the signs of scoliosis, kyphosis, lordosis, whether there is a difference in the height of the two shoulders and hips, the sagging status in the abdominal region, the presence of gibbosity, genu recurvatum, and the level of anterior balance by assigning a score between 0-3.
posture related conditions measurementday 1observational analysis by scapular dyskinesia test
posture related (scapular motion)conditions existence measurementday 1by lateral scapular slide test which evaluates distance between medial border of spine scapulae and T3 spinous process- T7 spinous process and inferior angle of scapulae
comorbidity assesment1 time which will be in one dayvia Charlson comorbidity index (values between 0-33)
evaluation of participation to daily life activitiesday 1Participation to daily life activities will be evaluated by London Chest Activities of Daily Living Questionnare. Contains 15 items grouped into four domains: self-care, household activities (domestic), physical, and leisure activities. Responses for each item range from 0-5, with 0 indicating wouldn't do anyway, 1-4 representing degree of breathlessness and 5 representing the greatest difficulty with performing ADL (someone else completes). Responses to items 1-15 are added; the total score can range from 0 to 75 points, with higher scores indicating greater functional limitation
pulmonary function measurementday 1evaluation of pulmonary function with lung function test which will be detected via FVC, FEV1, FEV1/FVC, PEF, FEF25-75% At least three technically acceptable measurements were obtained between the two best-measured FEV1 values, with no more than a 5% difference, and the best FEV1 value was selected for analysis.
investigation of diffusion capacity of the lungday 1by diffusion capacity of carbon monoxide of lung with single breath method
peripheral muscle strengthday 1by hand held dynamometry device
quality of life evaluationday 1Quality of life will be assessed by Saint George respiratory questionnaire. A total score is calculated from 0 (no health impairment) to 100 (maximum health impairment).

Countries

Turkey (Türkiye)

Contacts

Primary ContactAYNUR DEMIREL, Assoc. Prof.
aynur.demirel@hacettepe.edu.tr+9053123051576
Backup ContactAynur Demirel
aynurdemirel629@hotmail.com05545295057

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026